Theriva Biologics, Inc. (TOVX)Healthcare | Biotechnology | Rockville, United States | NYSE American
0.25 USD
-0.01
(-2.931%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 0.25 +0.00 (1.999%) ⇧ (Aug. 28, 2026, 7:50 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:44 a.m. EDT
The immediate outlook is severely clouded by a relentless multi-year price collapse. The stock has endured five consecutive years of negative annual returns, culminating in a catastrophic -100% loss over the last nine years. This trajectory is not merely a correction; it reflects a market verdict that the business fundamentals are failing to sustain value, evidenced by negative operating margins, negative free cash flow, and a trailing P/E that implies massive losses relative to price. While the company reports clinical progress in oncology trials and maintains a modest cash balance, the capital markets have priced in a high probability of dilution or failure, driving the price to pennies. There is no momentum to exploit here, as the statistical forecast models also register a weak bearish lean with low confidence. For investors, the risk of permanent capital loss outweighs any speculative hope of a turnaround, making this a clear avoidance candidate. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.148411 |
| AutoETS | 0.153375 |
| MSTL | 0.154118 |
| AutoTheta | 0.235843 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 7.02 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.274 |
| Excess Kurtosis | -0.15 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 29.154 |
| Revenue per Share | 0.01 |
| Market Cap | 11,248,293 |
| Trailing P/E | 0.18 |
| Forward P/E | -1.23 |
| Beta | 1.12 |
| Previous Name | Synthetic Biologics, Inc. |
| Website | https://therivabio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.3902439 |
| Address1 | 9,605 Medical Center Drive |
| Address2 | Suite 270 |
| All Time High | 262,500.0 |
| All Time Low | 0.16 |
| Ask | 0.2471 |
| Ask Size | 700 |
| Average Daily Volume10 Day | 603,180 |
| Average Daily Volume3 Month | 6,186,250 |
| Average Volume | 6,186,250 |
| Average Volume10Days | 603,180 |
| Beta | 1.118 |
| Bid | 0.2471 |
| Bid Size | 300 |
| Book Value | 0.266 |
| City | Rockville |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.2451 |
| Current Ratio | 1.129 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 0.2607 |
| Day Low | 0.2431 |
| Debt To Equity | 29.154 |
| Display Name | Theriva Biologics |
| Dividend Date | 1,534,118,400 |
| Earnings Call Timestamp End | 1,711,369,800 |
| Earnings Call Timestamp Start | 1,711,369,800 |
| Earnings Timestamp End | 1,755,174,600 |
| Earnings Timestamp Start | 1,755,174,600 |
| Ebitda | -11,963,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.29 |
| Enterprise To Revenue | 11.548 |
| Enterprise Value | 3,464,293 |
| Eps Current Year | -0.2 |
| Eps Forward | -0.2 |
| Eps Trailing Twelve Months | 1.4 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.235 |
| Fifty Day Average Change | 0.010100007 |
| Fifty Day Average Change Percent | 0.042978752 |
| Fifty Two Week Change Percent | -39.024387 |
| Fifty Two Week High | 0.86 |
| Fifty Two Week High Change | -0.6149 |
| Fifty Two Week High Change Percent | -0.715 |
| Fifty Two Week Low | 0.16 |
| Fifty Two Week Low Change | 0.08510001 |
| Fifty Two Week Low Change Percent | 0.5318751 |
| Fifty Two Week Range | 0.16 - 0.86 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,166,452,200,000 |
| Float Shares | 45,143,241 |
| Forward Eps | -0.2 |
| Forward P E | -1.2255 |
| Free Cashflow | -6,694,250 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 15 |
| Fullday Change | -0.00739999 |
| Fullday Change Percent | -2.93069 |
| Fullday Price | 0.25 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 300,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01633 |
| Held Percent Institutions | 0.0435 |
| Implied Shares Outstanding | 45,892,668 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.syntheticbiologics.com/investors |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,724,630,400 |
| Last Split Factor | 1:25 |
| Long Business Summary | Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland. |
| Long Name | Theriva Biologics, Inc. |
| Market | us_market |
| Market Cap | 11,248,293 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_24424557 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-08-28 |
| Net Income To Common | -13,128,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 11,587,898 |
| Number Of Analyst Opinions | 2 |
| Open | 0.2522 |
| Operating Cashflow | -12,742,000 |
| Operating Margins | -40.22 |
| Payout Ratio | 0.0 |
| Phone | 301 417 4364 |
| Post Market Change | 0.0048999935 |
| Post Market Change Percent | 1.9991813 |
| Post Market Price | 0.25 |
| Post Market Time | 1,787,961,003 |
| Prev Name | Synthetic Biologics, Inc. |
| Previous Close | 0.2525 |
| Price Eps Current Year | -1.2255 |
| Price Hint | 4 |
| Price To Book | 0.92142856 |
| Price To Sales Trailing12 Months | 37.49431 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.085 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.00739999 |
| Regular Market Change Percent | -2.93069 |
| Regular Market Day High | 0.2607 |
| Regular Market Day Low | 0.2431 |
| Regular Market Day Range | 0.2431 - 0.2607 |
| Regular Market Open | 0.2522 |
| Regular Market Previous Close | 0.2525 |
| Regular Market Price | 0.2451 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 559,452 |
| Return On Assets | -0.21337 |
| Return On Equity | -1.01868 |
| Revenue Per Share | 0.01 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 45,892,668 |
| Shares Percent Shares Out | 0.0374 |
| Shares Short | 1,716,998 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 2,336,498 |
| Short Name | Theriva Biologics, Inc. |
| Short Percent Of Float | 0.0374 |
| Short Ratio | 3.21 |
| Source Interval | 15 |
| State | MD |
| Symbol | TOVX |
| Target High Price | 4.0 |
| Target Low Price | 1.0 |
| Target Mean Price | 2.5 |
| Target Median Price | 2.5 |
| Total Cash | 11,337,000 |
| Total Cash Per Share | 0.247 |
| Total Debt | 3,553,000 |
| Total Revenue | 300,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 1.4 |
| Trailing P E | 0.17507143 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.24015 |
| Two Hundred Day Average Change | 0.004950002 |
| Two Hundred Day Average Change Percent | 0.020612124 |
| Type Disp | Equity |
| Volume | 559,452 |
| Website | https://therivabio.com |
| Zip | 20,850 |